Literature DB >> 2574361

Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis.

U Hopf1, B Möller, R Stemerowicz, H Lobeck, A Rodloff, M Freudenberg, C Galanos, D Huhn.   

Abstract

Since antimitochondrial antibodies (AMA) specific to primary biliary cirrhosis (PBC) recognise enterobacterial proteins and can be induced by R(rough)-mutants of enterobacteriaceae a study was done to find out the prevalence of enterobacterial R-forms in stool samples of patients with chronic inflammatory liver diseases. Liver biopsy specimens were also examined for lipid A, a common antigenic component of the cell wall in gram-negative bacteria. In all stool samples from the 21 patients with PBC Escherichia coli R-forms constituted up to half of the total amount of E coli. In contrast E coli R-forms were detectable in the stools of only 1 healthy control (n = 20), and in 25% of patients with other cholestatic diseases (n = 10), chronic hepatitis type B (n = 15), type non-A, non-B hepatitis (n = 15), or chronic pancreatitis and fat malabsorption (n = 8). An immunoblot technique showed that E coli R-forms isolated from patients' stools contained PBC-specific AMA-reactive proteins with molecular weights of 70-80 kD and 50 kD. Deposits of lipid A, located primarily in the cytoplasm of hepatocytes, were found in 11 patients with PBC but not in the liver of patients with chronic viral hepatitis. Circulating antibodies against lipid A were found rarely and in low titres. The data support the hypothesis that intestinal enterobacterial R-forms are aetiologically important in PBC and that antigens released from the bacterial cell wall contribute to the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574361     DOI: 10.1016/s0140-6736(89)92034-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  30 in total

Review 1.  Are the inflammatory bowel diseases autoimmune disorders?

Authors:  J Snook
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

2.  Enterococcus faecalis antigens in human infections.

Authors:  Y Xu; L Jiang; B E Murray; G M Weinstock
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

Review 3.  Mitochondrial antigens and antibodies in primary biliary cirrhosis.

Authors:  P Butler; F Valle; A K Burroughs
Journal:  Postgrad Med J       Date:  1991-09       Impact factor: 2.401

Review 4.  Recent developments in primary biliary cirrhosis: etiology and treatment.

Authors:  U Hopf; R Stemerowicz
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

5.  Escherichia coli infection induces autoimmune cholangitis and anti-mitochondrial antibodies in non-obese diabetic (NOD).B6 (Idd10/Idd18) mice.

Authors:  J J Wang; G-X Yang; W C Zhang; L Lu; K Tsuneyama; M Kronenberg; J L Véla; M Lopez-Hoyos; X-S He; W M Ridgway; P S C Leung; M E Gershwin
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

6.  Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments.

Authors:  Palak J Trivedi; Sue Cullen
Journal:  Hepatol Int       Date:  2012-03-20       Impact factor: 6.047

7.  Microbiome-Immune Interactions and Liver Disease.

Authors:  James H Tabibian; Cyril Varghese; Steven P O'Hara; Nicholas F LaRusso
Journal:  Clin Liver Dis (Hoboken)       Date:  2015-05-07

8.  Chlamydia pneumoniae replicates in Kupffer cells in mouse model of liver infection.

Authors:  Antonella Marangoni; Manuela Donati; Francesca Cavrini; Rita Aldini; Silvia Accardo; Vittorio Sambri; Marco Montagnani; Roberto Cevenini
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

9.  Contribution of gut bacteria to liver pathobiology.

Authors:  Gakuhei Son; Michael Kremer; Ian N Hines
Journal:  Gastroenterol Res Pract       Date:  2010-07-28       Impact factor: 2.260

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.